Abbott Kicks in for Bigfoot's $45M Financing

It may only be January, but it looks like 2020 could be Bigfoot Biomedical's year.

The company is on track to submit its Bigfoot Unity diabetes technology for FDA clearance this year, and the product could hit the market by the year end. To help the company reach that target, Abbott and other investors kicked in a total of $45 million in an initial tranche of a series C financing.